Pilot BA Study of New LY03005 vs Pristiq

NCT02988024 | Completed Phase 1

• 1 other identifier: LY03005/CT-USA-103
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.

Conditions

Major Depression

Outcome Measures

Primary Outcomes (1)

• Area under curve (AUC) for the Pharmacokinetics (PK) of LY03005

  PK Samples drawn at 0 (within 30 minutes prior to dosing), 1,2,3,4 (+/- 5 min), 6,8,10,12,23,32,48 and 72 hours (+/- 15 min) after dosing.

  4 days

Study Arms (2)

LY03005

EXPERIMENTAL

LY03005 80 mg

Drug: LY03005

Pristiq

ACTIVE COMPARATOR

Pristiq 50 mg

Drug: Pristiq

Interventions

LY03005 DRUG

LY03005

LY03005

Pristiq DRUG

Also known as: Desvenlafaxine

Pristiq

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Are capable of giving informed consent and complying with study procedures;
• Male and female subjects between the ages of 18 and 50 years;
• Considered healthy by the Principal Investigator, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs;
• Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6 months before screening based on subject report;
• Body mass index (BMI) of 19 to 30 kg/m 2 inclusive and body weight not less than 50 kg;
• Willing and able to adhere to study restrictions and to be confined at the clinical research center.
• All female subjects no matter of age must have a negative pregnancy test result at screening. In addition, female subjects must meet one of the following three conditions: (i) postmenopausal for at least 2 years, (ii) surgically sterile based on subject report, or (iii) if child-bearing potential, practicing or agree to practice an effective method of birth control by using an acceptable method of contraception.
• Acceptable methods of birth control include oral, injected, vaginal or patch contraceptive, IUD (Intrauterine device)(copper intrauterine device), or double- barrier method (e.g., condom, diaphragm or cervical cap with spermicidal foam, cream, gel or suppository). Acceptable methods of birth control must be used for at least 14 days prior to the use of study drug, during the study and within one month after the end of the study.

You may not qualify if:

• Clinically significant past history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, ophthalmological, or drug hypersensitivity;
• History of suicide attempt in the past 12 months and/or seen by the investigators having a significant history of risk of suicide or homicide;
• History or presence of malignancy other than adequately treated basal cell skin cancer;
• Clinically relevant illness within one month prior to the screening visit or at screening visit that may interfere with the conduct of this study;
• Subjects with a mean systolic blood pressure of three measurements \>140 mmHg, or a mean diastolic blood pressure of three measurements \>90 mmHg at screening;
• Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody;
• A history of seizure. However, a history of febrile seizure is allowed;
• A hospital admission or major surgery within 30 days prior to screening;
• Participation in any other investigational drug trial within 30 days prior to screening;
• A history of prescription drug abuse, or illicit drug use within 6 months prior to screening;
• A history of alcohol abuse according to medical history within 6 months prior to screening;
• A positive screen for alcohol, drugs of abuse;
• Tobacco use within 6 months prior to screening based on subject report;
• Subjects with hypersensitivity to PRISTIQ or medicines containing desvenlafaxine or its precursor venlafaxine;
• Subjects who have participated in a previous clinical study of either LY03005 or PRISTIQ or medicines containing desvenlafaxine or its precursor, venlafaxine within 30 days prior to screening;

Sponsors & Collaborators

• Luye Pharma Group Ltd.: lead

Study Sites (1)

Clinilabs, Inc.

Eatontown, New Jersey, 07724, United States

Location

MeSH Terms

Conditions

Depressive Disorder, Major

Interventions

Desvenlafaxine Succinate

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Cyclohexanols; Hexanols; Fatty Alcohols; Alcohols; Organic Chemicals; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Lipids

Study Officials

• Simon Li, M.D.

  Luye Pharma Group Ltd.

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 2, 2016
• First Posted: December 9, 2016
• Study Start: December 7, 2016
• Primary Completion: December 28, 2016
• Study Completion: December 28, 2016
• Last Updated: March 20, 2017

Record last verified: 2017-03

Locations

US (1)